Abbott Laboratories shares fall after quarterly revenue miss and soft guidance
Abbott Laboratories reported fourth-quarter revenue of $11.46 billion, missing estimates. The firm warned of headwinds in its diagnostics division for 2025.
Insights:
Abbott Laboratories reported fourth-quarter 2025 revenue of $11.46 billion, falling short of the Wall Street consensus estimate of $11.80 billion. Following the announcement, Abbott Laboratoriesshares fell nearly 4% in premarket trading. The US 
UShealthcare giant also issued profit guidance for the current quarter that came in below market expectations, signaling continued pressure on its financial outlook.
UShealthcare giant also issued profit guidance for the current quarter that came in below market expectations, signaling continued pressure on its financial outlook.The company's diagnostics division is a focal point of the report, as it faces a projected $700 million revenue decline in 2025. This downturn is attributed primarily to a steep drop-off in COVID-19 testing demand as global needs normalize following the pandemic peak. Additionally, pricing pressure from the China 
CNvolume-based procurement program for laboratory equipment and consumables is weighing on the division's performance.
CNvolume-based procurement program for laboratory equipment and consumables is weighing on the division's performance.
